Form 4 for AXGN Axogen, Inc.
Accepted 2026-08-12 16:12:49 ET · period of report 2026-08-11 · accession 0000805928-26-000098 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-08-12 16:12 | 2026-08-11 | AXGN | Wendell Amy McBride | Dir | M - OptEx | $14.85 | +13.4K | 121.3K | +12% | +$198.3K |
| DT | 2026-08-12 16:12 | 2026-08-11 | AXGN | Wendell Amy McBride | Dir | S - Sale+OE | $48.42 | -13.4K | 108.0K | -11% | -$646.6K |
| DT | 2026-08-12 16:12 | 2026-08-11 | AXGN | Wendell Amy McBride | Dir | M - OptEx | $0.00 | -13.4K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-11 | M | A | 13,353 | $14.85 | 121,329 | D | — | — | |
| 2 | Common | Common Stock | 2026-08-11 | S | D | 13,353 | $48.42 | 107,976 | D | — | — | (F1) The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2026. (F2) The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $47.82 to $49.02 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| 3 | Derivative | Employee Stock Option (right to purchase) | 2026-08-11 | M | D | 13,353 | $0.00 | 0 | D | $14.85 · — to 2027-06-01 | 13,353 Common Stock | (F3) All shares of Axogen, Inc. common stock underlying the board of director's stock option were fully vested on May 14, 2018. |